These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22169655)

  • 1. [Progress in clinicopathologic study on uterine smooth muscle tumor of uncertain malignant potential].
    Deng ZJ; Guo LN
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):573-6. PubMed ID: 22169655
    [No Abstract]   [Full Text] [Related]  

  • 2. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
    Ip PP; Cheung AN; Clement PB
    Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
    Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
    Mittal K; Demopoulos RI
    Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Uterine smooth muscle tumors: relationship between morphology and biologic behavior].
    Hui YZ
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):505-7. PubMed ID: 22169635
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
    Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
    Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
    Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
    Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.
    Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ
    Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is differential expression of p16INK4a based on the classification of uterine smooth muscle tumors associated with a different prognosis? A meta-analysis.
    Cao HY; Yang S; Wang S; Deng LY; Lou JY
    Genet Mol Res; 2017 Mar; 16(1):. PubMed ID: 28340268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
    Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
    Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions.
    Quade BJ
    Curr Opin Obstet Gynecol; 1995 Feb; 7(1):35-42. PubMed ID: 7742513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors.
    Gökaslan H; Türkeri L; Kavak ZN; Eren F; Sişmanoğlu A; Ilvan S; Durmuşoğlu F
    Gynecol Obstet Invest; 2005; 59(1):36-40. PubMed ID: 15377824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
    Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
    J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
    Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
    Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
    Petrović D; Babić D; Forko JI; Martinac I
    Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fascin expression in uterine smooth muscle tumors.
    Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
    Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual types of smooth muscle tumors of uterine corpus: case reports and literature review.
    Makharoblidze E; Goishvili N; Mchedlishvili M; Khakhutaishvili I; Jangavadze M
    Georgian Med News; 2013 Mar; (216):7-11. PubMed ID: 23567300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine leiomyosarcoma arising in leiomyoma: clinicopathological study of four cases and literature review.
    Yanai H; Wani Y; Notohara K; Takada S; Yoshino T
    Pathol Int; 2010 Jul; 60(7):506-9. PubMed ID: 20594271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
    Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
    Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.